Apoha Emerges from Stealth with $36M to Revolutionize Drug Development Through Molecular Behavior Analysis
核心洞察
Apoha (搜索), a London-based deeptech company, has emerged from stealth with $36 million in funding to commercialize its Liquid State Intelligence platform that measures how molecules behave under real-world conditions.
The company's VIBE platform can predict drug failure before clinical trials with greater than 90% precision using just 8 micrograms of material, potentially saving hundreds of millions of dollars per failed candidate.
Joint research with pharmaceutical giant Boehringer Ingelheim has validated the technology's ability to identify high-risk antibody candidates, while partnerships span across pharma, food, and materials sectors.
Apoha (搜索), a London-based deeptech company, has emerged from stealth with $36 million in Series A funding to commercialize its groundbreaking platform that measures molecular behavior under real-world conditions. The funding round, led by Singular (搜索) with participation from Tim Draper's Draper Associates (搜索) and continued backing from seed investors Redalpine, Seedcamp, Wilbe and Nucleus, alongside grant funding from Innovate UK, will advance what the company calls "Liquid State Intelligence" - a new category of molecular science.
Addressing a Critical Gap in Drug Development
The pharmaceutical industry has long struggled with a fundamental limitation: while scientists can determine what a molecule is from its sequence and what it looks like from its structure, they have been unable to predict how it will actually behave under real-world conditions. This (搜索) knowledge gap has contributed to costly drug failures in clinical trials, with companies making billion-dollar decisions based on incomplete information.
Apoha (搜索)'s solution addresses this (搜索) challenge through its VIBE (Variations in Inter-facial Behaviour Under Excitation) platform, which provides an empirical readout of how molecules, materials, or formulations behave under controlled stress conditions. The platform takes a sample small enough to fit on a pinhead, suspends it in liquid, applies a controlled series of stresses, and captures the wave patterns the molecule generates in response.
Validated Commercial Performance
The technology has demonstrated significant commercial validation through partnerships with major pharmaceutical companies. Joint research with Boehringer Ingelheim, a multi-year commercial partner, has shown that Apoha (搜索) can identify high-risk antibody candidates with greater than 90% precision from as little as 8 micrograms of material. This (搜索) capability represents a substantial advancement over conventional assays, which capture only one property at a time compared to VIBE's ability to resolve more than 1,000 measured descriptors of behavior in a single reading.
A second benchmarking study reported that the platform outperformed 12 industry-standard developability tests across 236 clinical antibodies, surfacing information that conventional measures miss rather than simply duplicating existing data.
Scientific Foundation and Patent Portfolio
The science behind Apoha (搜索) traces back to 2008, when founder and CEO Shamit Shrivastava began researching the physics of boundaries where matter meets liquids. His work on two-dimensional solitary sound waves at lipid interfaces, published in 2014, was later named among Scientific American's discoveries that could change everything. The research has since been cited more than 1,500 times across 19 papers.
Shrivastava co-founded Apoha (搜索) in 2021 with Anshika Srivastava, the company's COO and former Executive Director at Goldman Sachs (搜索). The company now holds more than 60 patents across hardware, software, data and AI models.
Expanding Applications Beyond Pharmaceuticals
While drug development represents a primary application, Apoha (搜索)'s technology extends across multiple sectors. The company is working with German biotech Ethris (搜索) on predicting how lipid nanoparticles (搜索) carrying mRNA (搜索) behave in animals, improving in-vitro to in-vivo correlation. Plant-based food company THIS (搜索) has used Apoha's technology to find protein replacements for supermarket products in record time.
The company also partners with Somru BioSciences (搜索) and multiple Fortune 500 companies across pharmaceutical, food and beverage, and materials sectors, demonstrating the broad applicability of molecular behavior analysis.
Implications for Physical-World AI
Beyond immediate commercial applications, Apoha (搜索) positions its technology as foundational infrastructure for the next generation of artificial intelligence systems that interact with the physical world. While AI models have learned to see and read, they have not yet learned to "feel" matter - to perceive how drugs respond to real-world conditions, how flavors are perceived, or how materials function under everyday stress.
"Liquid State Intelligence took 15 years of science and 5 years of company-building to bring to life," said Shamit Shrivastava. "There is no shortcut to this (搜索) data class — it cannot be scraped from the internet, synthesised, or retrofitted from existing assays. It has to be measured."
Raffi Kamber, Co-Founder and GP at Singular (搜索), noted that "Apoha (搜索) represents a new generation of European scientific companies where AI is not a future promise, but a practical tool already transforming how biology is done."
The funding will enable Apoha (搜索) to scale its platform and establish Liquid State Intelligence as a foundational data class for biologics, food, materials and physical-world AI applications, potentially transforming how companies approach product development across multiple industries.